[
  {
    "sentence": "We also summarize relevant studies on NK cells in breast cancer using small-molecule inhibitors, antibody therapies, and natural products and discuss the progress of preclinical and clinical trials (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Collectively, the above insights reveal that the adverse conditions prevalent in the TME, such as hypoxia, lactate accumulation, and limited glucose supply, affect NK cell function through multifaceted mechanisms (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This disruption leads to mitochondrial shrinkage and fragmentation, compromising the antitumor efficacy of NK cells.Metabolites\nNK cell functionality is modulated by several factors, including metabolites, such as ADO, IDO, and uric acid, and perturbations in serine-sphingolipid metabolism (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The TME of breast cancer encompasses a sophisticated network of cellular components, which collectively influence the functionality of NK cells (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, MSCs overexpressing SIRT1 can augment the antitumor capabilities of NK cells through the release of CXCL10 and IFN-γ.Immune-activating cells in the breast cancer TME\nTILs\nImmunoactivating and immunosuppressive cells within the TME exert distinctly different effects on NK cells (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Studies have found that knocking out STYK1 reduces CCR2 expression, inhibits the accumulation of NK cells in the TME, and promotes spontaneous breast tumor progression 165.Emerging therapeutic strategies targeting the TME\nSmall-molecule inhibitor-based therapies\nEmerging therapeutic strategies targeting the TME represent a frontier in cancer treatment, offering new hope for enhancing NK cell activity (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We also summarize relevant studies on NK cells in breast cancer using small-molecule inhibitors, antibody therapies, and natural products and discuss the progress of preclinical and clinical trials (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Collectively, the above insights reveal that the adverse conditions prevalent in the TME, such as hypoxia, lactate accumulation, and limited glucose supply, affect NK cell function through multifaceted mechanisms (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This disruption leads to mitochondrial shrinkage and fragmentation, compromising the antitumor efficacy of NK cells.Metabolites\nNK cell functionality is modulated by several factors, including metabolites, such as ADO, IDO, and uric acid, and perturbations in serine-sphingolipid metabolism (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The TME of breast cancer encompasses a sophisticated network of cellular components, which collectively influence the functionality of NK cells (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, MSCs overexpressing SIRT1 can augment the antitumor capabilities of NK cells through the release of CXCL10 and IFN-γ.Immune-activating cells in the breast cancer TME\nTILs\nImmunoactivating and immunosuppressive cells within the TME exert distinctly different effects on NK cells (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Studies have found that knocking out STYK1 reduces CCR2 expression, inhibits the accumulation of NK cells in the TME, and promotes spontaneous breast tumor progression 165.Emerging therapeutic strategies targeting the TME\nSmall-molecule inhibitor-based therapies\nEmerging therapeutic strategies targeting the TME represent a frontier in cancer treatment, offering new hope for enhancing NK cell activity (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We also summarize relevant studies on NK cells in breast cancer using small-molecule inhibitors, antibody therapies, and natural products and discuss the progress of preclinical and clinical trials (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Collectively, the above insights reveal that the adverse conditions prevalent in the TME, such as hypoxia, lactate accumulation, and limited glucose supply, affect NK cell function through multifaceted mechanisms (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This disruption leads to mitochondrial shrinkage and fragmentation, compromising the antitumor efficacy of NK cells.Metabolites\nNK cell functionality is modulated by several factors, including metabolites, such as ADO, IDO, and uric acid, and perturbations in serine-sphingolipid metabolism (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The TME of breast cancer encompasses a sophisticated network of cellular components, which collectively influence the functionality of NK cells (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, MSCs overexpressing SIRT1 can augment the antitumor capabilities of NK cells through the release of CXCL10 and IFN-γ.Immune-activating cells in the breast cancer TME\nTILs\nImmunoactivating and immunosuppressive cells within the TME exert distinctly different effects on NK cells (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Studies have found that knocking out STYK1 reduces CCR2 expression, inhibits the accumulation of NK cells in the TME, and promotes spontaneous breast tumor progression 165.Emerging therapeutic strategies targeting the TME\nSmall-molecule inhibitor-based therapies\nEmerging therapeutic strategies targeting the TME represent a frontier in cancer treatment, offering new hope for enhancing NK cell activity (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We also summarize relevant studies on NK cells in breast cancer using small-molecule inhibitors, antibody therapies, and natural products and discuss the progress of preclinical and clinical trials (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Collectively, the above insights reveal that the adverse conditions prevalent in the TME, such as hypoxia, lactate accumulation, and limited glucose supply, affect NK cell function through multifaceted mechanisms (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This disruption leads to mitochondrial shrinkage and fragmentation, compromising the antitumor efficacy of NK cells.Metabolites\nNK cell functionality is modulated by several factors, including metabolites, such as ADO, IDO, and uric acid, and perturbations in serine-sphingolipid metabolism (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The TME of breast cancer encompasses a sophisticated network of cellular components, which collectively influence the functionality of NK cells (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, MSCs overexpressing SIRT1 can augment the antitumor capabilities of NK cells through the release of CXCL10 and IFN-γ.Immune-activating cells in the breast cancer TME\nTILs\nImmunoactivating and immunosuppressive cells within the TME exert distinctly different effects on NK cells (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Studies have found that knocking out STYK1 reduces CCR2 expression, inhibits the accumulation of NK cells in the TME, and promotes spontaneous breast tumor progression 165.Emerging therapeutic strategies targeting the TME\nSmall-molecule inhibitor-based therapies\nEmerging therapeutic strategies targeting the TME represent a frontier in cancer treatment, offering new hope for enhancing NK cell activity (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We also summarize relevant studies on NK cells in breast cancer using small-molecule inhibitors, antibody therapies, and natural products and discuss the progress of preclinical and clinical trials (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Collectively, the above insights reveal that the adverse conditions prevalent in the TME, such as hypoxia, lactate accumulation, and limited glucose supply, affect NK cell function through multifaceted mechanisms (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This disruption leads to mitochondrial shrinkage and fragmentation, compromising the antitumor efficacy of NK cells.Metabolites\nNK cell functionality is modulated by several factors, including metabolites, such as ADO, IDO, and uric acid, and perturbations in serine-sphingolipid metabolism (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The TME of breast cancer encompasses a sophisticated network of cellular components, which collectively influence the functionality of NK cells (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, MSCs overexpressing SIRT1 can augment the antitumor capabilities of NK cells through the release of CXCL10 and IFN-γ.Immune-activating cells in the breast cancer TME\nTILs\nImmunoactivating and immunosuppressive cells within the TME exert distinctly different effects on NK cells (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Studies have found that knocking out STYK1 reduces CCR2 expression, inhibits the accumulation of NK cells in the TME, and promotes spontaneous breast tumor progression 165.Emerging therapeutic strategies targeting the TME\nSmall-molecule inhibitor-based therapies\nEmerging therapeutic strategies targeting the TME represent a frontier in cancer treatment, offering new hope for enhancing NK cell activity (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We also summarize relevant studies on NK cells in breast cancer using small-molecule inhibitors, antibody therapies, and natural products and discuss the progress of preclinical and clinical trials (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Collectively, the above insights reveal that the adverse conditions prevalent in the TME, such as hypoxia, lactate accumulation, and limited glucose supply, affect NK cell function through multifaceted mechanisms (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This disruption leads to mitochondrial shrinkage and fragmentation, compromising the antitumor efficacy of NK cells.Metabolites\nNK cell functionality is modulated by several factors, including metabolites, such as ADO, IDO, and uric acid, and perturbations in serine-sphingolipid metabolism (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The TME of breast cancer encompasses a sophisticated network of cellular components, which collectively influence the functionality of NK cells (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, MSCs overexpressing SIRT1 can augment the antitumor capabilities of NK cells through the release of CXCL10 and IFN-γ.Immune-activating cells in the breast cancer TME\nTILs\nImmunoactivating and immunosuppressive cells within the TME exert distinctly different effects on NK cells (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Studies have found that knocking out STYK1 reduces CCR2 expression, inhibits the accumulation of NK cells in the TME, and promotes spontaneous breast tumor progression 165.Emerging therapeutic strategies targeting the TME\nSmall-molecule inhibitor-based therapies\nEmerging therapeutic strategies targeting the TME represent a frontier in cancer treatment, offering new hope for enhancing NK cell activity (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We also summarize relevant studies on NK cells in breast cancer using small-molecule inhibitors, antibody therapies, and natural products and discuss the progress of preclinical and clinical trials (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Collectively, the above insights reveal that the adverse conditions prevalent in the TME, such as hypoxia, lactate accumulation, and limited glucose supply, affect NK cell function through multifaceted mechanisms (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This disruption leads to mitochondrial shrinkage and fragmentation, compromising the antitumor efficacy of NK cells.Metabolites\nNK cell functionality is modulated by several factors, including metabolites, such as ADO, IDO, and uric acid, and perturbations in serine-sphingolipid metabolism (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The TME of breast cancer encompasses a sophisticated network of cellular components, which collectively influence the functionality of NK cells (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, MSCs overexpressing SIRT1 can augment the antitumor capabilities of NK cells through the release of CXCL10 and IFN-γ.Immune-activating cells in the breast cancer TME\nTILs\nImmunoactivating and immunosuppressive cells within the TME exert distinctly different effects on NK cells (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Studies have found that knocking out STYK1 reduces CCR2 expression, inhibits the accumulation of NK cells in the TME, and promotes spontaneous breast tumor progression 165.Emerging therapeutic strategies targeting the TME\nSmall-molecule inhibitor-based therapies\nEmerging therapeutic strategies targeting the TME represent a frontier in cancer treatment, offering new hope for enhancing NK cell activity (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We also summarize relevant studies on NK cells in breast cancer using small-molecule inhibitors, antibody therapies, and natural products and discuss the progress of preclinical and clinical trials (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Collectively, the above insights reveal that the adverse conditions prevalent in the TME, such as hypoxia, lactate accumulation, and limited glucose supply, affect NK cell function through multifaceted mechanisms (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This disruption leads to mitochondrial shrinkage and fragmentation, compromising the antitumor efficacy of NK cells.Metabolites\nNK cell functionality is modulated by several factors, including metabolites, such as ADO, IDO, and uric acid, and perturbations in serine-sphingolipid metabolism (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The TME of breast cancer encompasses a sophisticated network of cellular components, which collectively influence the functionality of NK cells (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, MSCs overexpressing SIRT1 can augment the antitumor capabilities of NK cells through the release of CXCL10 and IFN-γ.Immune-activating cells in the breast cancer TME\nTILs\nImmunoactivating and immunosuppressive cells within the TME exert distinctly different effects on NK cells (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Studies have found that knocking out STYK1 reduces CCR2 expression, inhibits the accumulation of NK cells in the TME, and promotes spontaneous breast tumor progression 165.Emerging therapeutic strategies targeting the TME\nSmall-molecule inhibitor-based therapies\nEmerging therapeutic strategies targeting the TME represent a frontier in cancer treatment, offering new hope for enhancing NK cell activity (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We also summarize relevant studies on NK cells in breast cancer using small-molecule inhibitors, antibody therapies, and natural products and discuss the progress of preclinical and clinical trials (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We also summarize relevant studies on NK cells in breast cancer using small-molecule inhibitors, antibody therapies, and natural products and discuss the progress of preclinical and clinical trials (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Collectively, the above insights reveal that the adverse conditions prevalent in the TME, such as hypoxia, lactate accumulation, and limited glucose supply, affect NK cell function through multifaceted mechanisms (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This disruption leads to mitochondrial shrinkage and fragmentation, compromising the antitumor efficacy of NK cells.Metabolites\nNK cell functionality is modulated by several factors, including metabolites, such as ADO, IDO, and uric acid, and perturbations in serine-sphingolipid metabolism (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Collectively, the above insights reveal that the adverse conditions prevalent in the TME, such as hypoxia, lactate accumulation, and limited glucose supply, affect NK cell function through multifaceted mechanisms (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Collectively, the above insights reveal that the adverse conditions prevalent in the TME, such as hypoxia, lactate accumulation, and limited glucose supply, affect NK cell function through multifaceted mechanisms (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Metabolites\nNK cell functionality is modulated by several factors, including metabolites, such as ADO, IDO, and uric acid, and perturbations in serine-sphingolipid metabolism (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "NK cell functionality is modulated by several factors, including metabolites, such as ADO, IDO, and uric acid, and perturbations in serine-sphingolipid metabolism (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The TME of breast cancer encompasses a sophisticated network of cellular components, which collectively influence the functionality of NK cells (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The TME of breast cancer encompasses a sophisticated network of cellular components, which collectively influence the functionality of NK cells (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The TME of breast cancer encompasses a sophisticated network of cellular components, which collectively influence the functionality of NK cells (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Immune-activating cells in the breast cancer TME\nTILs\nImmunoactivating and immunosuppressive cells within the TME exert distinctly different effects on NK cells (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "TILs\nImmunoactivating and immunosuppressive cells within the TME exert distinctly different effects on NK cells (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Immunoactivating and immunosuppressive cells within the TME exert distinctly different effects on NK cells (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Emerging therapeutic strategies targeting the TME\nSmall-molecule inhibitor-based therapies\nEmerging therapeutic strategies targeting the TME represent a frontier in cancer treatment, offering new hope for enhancing NK cell activity (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Small-molecule inhibitor-based therapies\nEmerging therapeutic strategies targeting the TME represent a frontier in cancer treatment, offering new hope for enhancing NK cell activity (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Emerging therapeutic strategies targeting the TME represent a frontier in cancer treatment, offering new hope for enhancing NK cell activity (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  }
]